34287358|t|Preparation, Optimization and Evaluation of Chitosan-Based Avanafil Nanocomplex Utilizing Antioxidants for Enhanced Neuroprotective Effect on PC12 Cells.
34287358|a|(1) Introduction: in recent decades, interdisciplinary research on the utilization of natural products as "active moiety carriers" was focused on due to their superior safety profile, biodegradability, biocompatibility and the ability for sustained or controlled release activity. The nano-based neuroprotective strategy is explored as an imperative treatment for diabetic neuropathy (DN). Avanafil (AV), that selectively inhibits the degradation of cGMP-specific phosphodiesterase, thereby increasing the levels of cGMP, makes a decisive mediator for cytoprotection. (2) Methods: AVnanocomplex formulations were prepared by a modified anti-solvent precipitation method and the method was optimized by Box-Behnken design. An optimized formulation was characterized and evaluated for various in vitro parameters; (3) results:based on the desirability approach, the formulation containing 2.176 g of chitosan, 7.984 g of zein and 90% v/v ethanol concentration can fulfill the prerequisites of optimum formulation (OB-AV-NC).OB-AV-NC was characterized and evaluated for various parameters. The neuroprotective mechanism of AV was evaluated by pretreatment of PC12 cells with plain AV, avanafil nanocomplex (NC) without antioxidants (AV-NC) and with antioxidants (alpha-Lipoic acid LP; Ellagic Acid EA), AV-LP-EA-Nanocomplex has also shown considerable attenuation in intracellular reactive oxygen species (ROS) and lipid peroxidation with a significant increase in the PC 12 viability under HG conditions in comparison to pure AV; (4) conclusion: the nanocomplex of AV prepared to utilize natural polymers and antioxidants aided for high solubility of AV and exhibited desired neuroprotective activity.This can be one of the promisingstrategy to translate the AV nanocomplex with safety and efficacy in treating DN.
34287358	44	52	Chitosan	Chemical	MESH:D048271
34287358	59	67	Avanafil	Chemical	MESH:C553414
34287358	68	79	Nanocomplex	Chemical	-
34287358	142	146	PC12	CellLine	CVCL:0481
34287358	518	537	diabetic neuropathy	Disease	MESH:D003929
34287358	539	541	DN	Disease	MESH:D003929
34287358	544	552	Avanafil	Chemical	MESH:C553414
34287358	554	556	AV	Chemical	MESH:C553414
34287358	670	674	cGMP	Chemical	MESH:D006152
34287358	735	748	AVnanocomplex	Chemical	-
34287358	1052	1060	chitosan	Chemical	MESH:D048271
34287358	1090	1097	ethanol	Chemical	MESH:D000431
34287358	1169	1171	AV	Chemical	MESH:C553414
34287358	1179	1181	AV	Chemical	MESH:C553414
34287358	1274	1276	AV	Chemical	MESH:C553414
34287358	1310	1314	PC12	CellLine	CVCL:0481
34287358	1332	1334	AV	Chemical	MESH:C553414
34287358	1336	1344	avanafil	Chemical	MESH:C553414
34287358	1345	1356	nanocomplex	Chemical	-
34287358	1384	1386	AV	Chemical	MESH:C553414
34287358	1414	1434	alpha-Lipoic acid LP	Chemical	-
34287358	1436	1448	Ellagic Acid	Chemical	MESH:D004610
34287358	1449	1451	EA	Chemical	MESH:D004976
34287358	1454	1462	AV-LP-EA	Chemical	-
34287358	1463	1474	Nanocomplex	Chemical	-
34287358	1532	1555	reactive oxygen species	Chemical	MESH:D017382
34287358	1557	1560	ROS	Chemical	MESH:D017382
34287358	1566	1571	lipid	Chemical	MESH:D008055
34287358	1620	1625	PC 12	Chemical	MESH:C084257
34287358	1678	1680	AV	Chemical	MESH:C553414
34287358	1702	1713	nanocomplex	Chemical	-
34287358	1717	1719	AV	Chemical	MESH:C553414
34287358	1748	1756	polymers	Chemical	MESH:D011108
34287358	1803	1805	AV	Chemical	MESH:C553414
34287358	1911	1913	AV	Chemical	MESH:C553414
34287358	1914	1925	nanocomplex	Chemical	-
34287358	1963	1965	DN	Disease	MESH:D003929
34287358	Negative_Correlation	MESH:C553414	MESH:D048271
34287358	Negative_Correlation	MESH:C553414	MESH:D003929
34287358	Positive_Correlation	MESH:C553414	MESH:D006152

